Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Medtronic
Dow
Baxter

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CAPECITABINE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Capecitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003704 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed National Cancer Institute (NCI) Phase 1 1999-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.
NCT00003704 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed Alliance for Clinical Trials in Oncology Phase 1 1999-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.
NCT00003867 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status Albert Einstein College of Medicine of Yeshiva University Phase 1 1999-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.
NCT00003902 Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement Completed Swiss Group for Clinical Cancer Research Phase 1/Phase 2 1999-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine and vinorelbine and to see how well they work in treating older women with metastatic breast cancer with or without bone involvement.
NCT00004012 Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed National Cancer Institute (NCI) Phase 2 1998-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
NCT00004012 Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 1998-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
NCT00004183 Capecitabine in Treating Patients With Malignant Mesothelioma Completed National Cancer Institute (NCI) Phase 2 2000-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have malignant mesothelioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Capecitabine

Condition Name

Condition Name for Capecitabine
Intervention Trials
Breast Cancer 186
Colorectal Cancer 150
Gastric Cancer 95
Pancreatic Cancer 71
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Capecitabine
Intervention Trials
Breast Neoplasms 322
Colorectal Neoplasms 268
Stomach Neoplasms 171
Rectal Neoplasms 141
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Capecitabine

Trials by Country

Trials by Country for Capecitabine
Location Trials
China 259
Italy 247
Austria 65
Argentina 56
Taiwan 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Capecitabine
Location Trials
California 163
Texas 146
New York 135
Florida 119
Ohio 107
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Capecitabine

Clinical Trial Phase

Clinical Trial Phase for Capecitabine
Clinical Trial Phase Trials
Phase 4 20
Phase 3 229
Phase 2/Phase 3 41
[disabled in preview] 1013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Capecitabine
Clinical Trial Phase Trials
Completed 493
Recruiting 253
Unknown status 142
[disabled in preview] 405
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Capecitabine

Sponsor Name

Sponsor Name for Capecitabine
Sponsor Trials
National Cancer Institute (NCI) 160
Hoffmann-La Roche 128
Sanofi 59
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Capecitabine
Sponsor Trials
Other 1332
Industry 664
NIH 161
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKinsey
McKesson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.